Yamanouchi Signs Deal With Celera
%mlink(STRY:; PHOTO:; AUDIO:%)
ROCKVILLE, Md. (AP) _ Japanese drug maker Yamanouchi Pharmaceutical has signed a five-year subscription deal with Celera Genomics Corp.
Yamanouchi will gain access to Celera’s Discovery System, the company’s online library of genetic information for humans, mice and other organisms.
Terms of the agreement were not released, but Celera’s subscription fees reportedly run from roughly $10,000 for academic researchers to several million for large pharmaceutical companies.
Yamanouchi, the third-largest drug company in Japan, is Celera’s second Japanese database customer. Takeda Chemical Industries Ltd. signed a contract with Celera in March 2000.